The lead
CNBC Top Newscompaniescorporate event
AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes (opens at CNBC Top News in a new tab)
AstraZeneca's COPD drug achieved positive results in two late-stage trials. Full data support its potential as a breakthrough treatment and its peak annual sales forecast above $5 billion.
Continue at CNBC Top News